House Committee Investigates Eli Lilly's Clinical Trials in China

The House Select Committee on the Chinese Communist Party, led by Chairman John Moolenaar, is investigating Eli Lilly's clinical trial operations in China. The committee has requested records related to research conducted at hospitals affiliated with the Chinese military and in Xinjiang. In a letter dated June 30, 2026, Moolenaar requested detailed information on how Eli Lilly ensures ethical standards and protects sensitive biotechnology and intellectual property in its clinical trials. The committee noted that Eli Lilly has sponsored over 220 clinical studies in China since 2003, including trials in Xinjiang and at military medical centers. The inquiry reflects growing concerns among lawmakers regarding the potential national security and human rights risks associated with U.S. pharmaceutical companies' ties to China. Moolenaar emphasized that there is no evidence of illegal activity by Eli Lilly but expressed concerns about the implications of conducting trials in regions with documented human rights abuses. The letter also raises questions about the adequacy of participant protections in China's clinical trial system. Eli Lilly has until July 17 to respond to the committee's requests for documentation.